TY - JOUR
T1 - Implications of mutation profiling in myeloid malignancies
T2 - Part 2: Myeloproliferative neoplasms and other myeloid malignancies
AU - Sokol, Kelsey
AU - Tremblay, Douglas
AU - Bhalla, Sheena
AU - Rampal, Raajit
AU - Mascarenhas, John O.
N1 - Funding Information:
Financial Disclosure: Dr. Stearns receives research support from AbbVie, Biocept, MedImmune, Novartis, Pfizer, and Puma. Drs. Shah and Nunes have no significant financial interest in or other relationship with the manufacturer of any product mentioned in this article.
Funding Information:
Financial Disclosure: Dr. Jones has received advisory board and speaker honoraria from Janssen, as well as speaker honoraria and research funding from Sanofi Genzyme.
Funding Information:
Aramont Foundation and Canales de Ayuda Foundation for their support of Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán Urologic Oncology Clinic research projects.
Funding Information:
Acknowledgment: This article was supported in part through the National Institutes of Health/National Cancer Institute Cancer Center Support Grant P30 CA008748.
Publisher Copyright:
© 2018, UBM Medica Healthcare Publications. All rights reserved.
PY - 2018
Y1 - 2018
N2 - Myeloid malignancies arise from the acquisition of somatic mutations among various genes implicated in essential functioning of hematopoietic stem cells and progenitor cells. In this second part of our two-part review, we discuss the use of mutation profiling in the diagnosis, prognosis, and treatment of patients with myeloproliferative neoplasms and other myeloid diseases. We also discuss the entity known as clonal hematopoiesis of indeterminate potential, awareness of which is a result of the increasing availability and improved quality of mutation profiling.
AB - Myeloid malignancies arise from the acquisition of somatic mutations among various genes implicated in essential functioning of hematopoietic stem cells and progenitor cells. In this second part of our two-part review, we discuss the use of mutation profiling in the diagnosis, prognosis, and treatment of patients with myeloproliferative neoplasms and other myeloid diseases. We also discuss the entity known as clonal hematopoiesis of indeterminate potential, awareness of which is a result of the increasing availability and improved quality of mutation profiling.
UR - http://www.scopus.com/inward/record.url?scp=85059642938&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85059642938&partnerID=8YFLogxK
M3 - Article
C2 - 29847855
AN - SCOPUS:85059642938
SN - 0890-9091
VL - 32
SP - e45-e51
JO - ONCOLOGY (United States)
JF - ONCOLOGY (United States)
IS - 5
ER -